This profile confers selective dependencies in OXPHOS-dep. tRCC cells. e.g tRCCs show selective dep on EGLN1. Inhibiting EGLN1 stabilizes HIF-1α, leading to glycolytic reprogramming. EGLN inhibitors, approved for anemia treatment, could perhaps be explored for tRCC & other OXPHOS-high cancers 💊. 3/
